Construction of whole-course management mode of selective internal radiotherapy with Yttrium-90 microspheres for malignant liver tumors

doi:10.3877/cma.j.issn.2095-3232.2026.03.010

Abstract

Abstract:

Objective

To construct the whole-course management mode of selective internal radiotherapy using Yttrium-90 microspheres (⁹⁰Y-SIRT) for malignant liver tumors.

Methods

Since the first case of ⁹⁰Y-SIRT was carried out in the First Affiliated Hospital of Jinan University in October 2022, ⁹⁰Y-SIRT has been performed in 300 cases. Based on clinical experience, a ⁹⁰Y-SIRT treatment system with its own characteristics was formed by continuously optimizing the treatment process, strengthening multidisciplinary cooperation and improving medical quality. In addition, whole-course management mode of ⁹⁰Y-SIRT for patients with malignant liver tumors was constructed. The whole-course management mode mainly covers three aspects: (1) medical guidance for ⁹⁰Y-SIRT; (2) standardized treatment of ⁹⁰Y-SIRT; (3) post-⁹⁰Y-SIRT follow-up. This mode ensures that patients can receive standardized, comprehensive and systematic treatment through multidisciplinary cooperation, information management and personalized nursing care.

Results

A whole-course management mode of ⁹⁰Y-SIRT covering medical guidance, standardized treatment and post-⁹⁰Y-SIRT follow-up was successfully constructed. Subjective and objective evaluation indexes of this mode were proposed. The whole-course management mode guarantees that all aspects of patients are fully considered and managed according to scientific and standardized medical guidance, treatment process and follow-up system. Formulation and implementation of multidisciplinary cooperation and individualized treatment regimen enhanced treatment specificity and effectiveness, lowered the incidence of complications and improved the quality of life of patients.The whole-course management mode integrated multidisciplinary resources and optimized treatment process as well as the allocation of medical resources and improved the efficiency and quality of medical services. By making full use of professional knowledge and technological advantages of various disciplines, this mode provided patients with more comprehensive and personalized treatment regimens. Meantime, by optimizing treatment process and reducing unnecessary examination and treatment procedures, it lowered medical costs and enhanced the efficiency and quality of medical services. The whole-course management mode adhered to the patient-centered service concept and highlighted the communication and exchange with patients. By answering patients' questions in a timely manner and caring about their needs and willingness, this mode increased patients' compliance and the degree of satisfaction. Psychological support and counseling could help patients to alleviate anxiety, fear and negative emotions, and improve their quality of life. Besides, it delivered personalized rehabilitation guidance and suggestions to promote patients' physical rehabilitation and social function recovery.

Conclusions

In our center, a scientific management mode of ⁹⁰Y-SIRT is successfully constructed, which is helpful to improve clinical efficacy, the degree of satisfaction and quality of life, and reduce adverse reactions. It also establishes the evaluation indexes of the whole-course management mode, providing evidence for comprehensively evaluating the implementation effect of the whole-course management mode.

Key words: Malignant hepatic tumor, Yttrium-90 microspheres, Selective internal radiation therapy, Whole-process management

Quan Jiang, Kangshou Liu, Zilin Wang, Yong Cheng, Yulong Liu, Yanbin Ye, Jian Sun, Mingrong Cao, Xiaolong Chen. Construction of whole-course management mode of selective internal radiotherapy with Yttrium-90 microspheres for malignant liver tumors[J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2026, 15(03): 362-371.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhgzwkssxdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3232.2026.03.010

https://zhgzwkssxdzzz.cma-cmc.com.cn/EN/Y2026/V15/I03/362

References 33

[1]	Rumgay H, Arnold M, Ferlay J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040[J]. J Hepatol, 2022, 77(6): 1598-1606. DOI: 10.1016/j.jhep.2022.08.021.
[2]	曹梦迪, 王红, 石菊芳, 等. 中国人群肝癌疾病负担: 多数据源证据更新整合分析[J]. 中华流行病学杂志, 2020, 41(11): 1848-1858. DOI: 10.3760/cma.j.cn112338-20200306-00271.
[3]	Cao W, Chen HD, Yu YW, et al. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020[J]. Chin Med J, 2021, 134(7): 783-791. DOI: 10.1097/CM9.0000000000001474.
[4]	Salem R, Gordon AC, Mouli S, et al. Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma[J]. Gastroenterology, 2016, 151(6): 1155-1163. e2. DOI: 10.1053/j.gastro.2016.08.029.
[5]	Garin E, Tselikas L, Guiu B, et al. Long-term overall survival after selective internal radiation therapy for locally advanced hepatocellular carcinomas: updated analysis of DOSISPHERE-01 trial[J]. J Nucl Med, 2024, 65(2): 264-269. DOI: 10.2967/jnumed.123.266211.
[6]	中国医师协会介入医师分会临床诊疗指南专委会, 中国研究型医院学会肝胆胰外科专业委员会. 钇-90微球选择性内放射治疗肝脏恶性肿瘤规范化操作专家共识(2024版)[J]. 中华医学杂志, 2024, 104(7): 486-498. DOI: 10.3760/cma.j.cn112137-20231025-00894.
[7]	中华人民共和国国家卫生健康委员会医政司. 原发性肝癌诊疗指南(2024年版)[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(4): 407-449. DOI: 10.3877/cma.j.issn.2095-3232.2024.04.001.
[8]	中国临床肿瘤学会核医学专家委员会, 北京市核医学质量控制和改进中心.钇-90(⁹⁰Y)微球选择性内放射治疗原发性和转移性肝癌的中国专家共识[J]. 中华肝脏病杂志, 2021, 29(7): 648-658. DOI: 10.3760/cma.j.cn501113-20210302-00103.
[9]	Dezarn WA, Cessna JT, DeWerd LA, et al. Recommendations of the American Association of Physicists in Medicine on dosimetry, imaging, and quality assurance procedures for 90Y microsphere brachytherapy in the treatment of hepatic malignancies[J]. Med Phys, 2011, 38(8): 4824-4845. DOI: 10.1118/1.3608909.
[10]	Lau WY, Kennedy AS, Kim YH, et al. Patient selection and activity planning guide for selective internal radiotherapy with yttrium-90 resin microspheres[J]. Int J Radiat Oncol Biol Phys, 2012, 82(1): 401-407. DOI: 10.1016/j.ijrobp.2010.08.015.
[11]	Villalobos A, Soliman MM, Majdalany BS, et al. Yttrium-90 radioembolization dosimetry: what trainees need to know[J]. Semin Intervent Radiol, 2020, 37(5): 543-554. DOI: 10.1055/s-0040-1720954.
[12]	Riaz A, Awais R, Salem R. Side effects of yttrium-90 radioembolization[J]. Front Oncol, 2014, 4: 198. DOI: 10.3389/fonc.2014.00198.
[13]	Riaz A, Lewandowski RJ, Kulik LM, et al. Complications following radioembolization with yttrium-90 microspheres: a comprehensive literature review[J]. J Vasc Interv Radiol, 2009, 20(9): 1121-1130; quiz1131. DOI: 10.1016/j.jvir.2009.05.030.
[14]	Leung TW, Lau WY, Ho SK, et al. Radiation pneumonitis after selective internal radiation treatment with intraarterial 90yttrium-microspheres for inoperable hepatic tumors[J]. Int J Radiat Oncol Biol Phys, 1995, 33(4): 919-924. DOI: 10.1016/0360-3016(95)00039-3.
[15]	Salem R, Parikh P, Atassi B, et al. Incidence of radiation pneumonitis after hepatic intra-arterial radiotherapy with yttrium-90 microspheres assuming uniform lung distribution[J]. Am J Clin Oncol, 2008, 31(5): 431-438. DOI: 10.1097/COC.0b013e318168ef65.
[16]	Kim HC, Kim GM. Radiation pneumonitis following Yttrium-90 radioembolization: a Korean multicenter study[J]. Front Oncol, 2023, 13: 977160. DOI: 10.3389/fonc.2023.977160.
[17]	Szyszko T, Al-Nahhas A, Tait P, et al. Management and prevention of adverse effects related to treatment of liver tumours with 90Y microspheres[J]. Nucl Med Commun, 2007, 28(1): 21-24. DOI: 10.1097/MNM.0b013e3280121a8f.
[18]	Murthy R, Brown DB, Salem R, et al. Gastrointestinal complications associated with hepatic arterial yttrium-90 microsphere therapy[J]. J Vasc Interv Radiol, 2007, 18(4): 553-561. DOI: 10.1016/j.jvir.2007.02.002.
[19]	Atassi B, Bangash AK, Lewandowski RJ, et al. Biliary sequelae following radioembolization with Yttrium-90 microspheres[J]. J Vasc Interv Radiol, 2008, 19(5): 691-697. DOI: 10.1016/j.jvir.2008.01.003.
[20]	Sangro B, Gil-Alzugaray B, Rodriguez J, et al. Liver disease induced by radioembolization of liver tumors: description and possible risk factors[J]. Cancer, 2008, 112(7): 1538-1546. DOI: 10.1002/cncr.23339.
[21]	Kennedy AS, McNeillie P, Dezarn WA, et al. Treatment parameters and outcome in 680 treatments of internal radiation with resin 90Y-microspheres for unresectable hepatic tumors[J]. Int J Radiat Oncol, 2009, 74(5): 1494-1500. DOI: 10.1016/j.ijrobp.2008.10.005.
[22]	Sag AA, Savin MA, Lal NR, et al. Yttrium-90 radioembolization of malignant tumors of the liver: gallbladder effects[J]. AJR Am J Roentgenol, 2014, 202(5): 1130-1135. DOI: 10.2214/AJR.13.10548.
[23]	Salem R, Lewandowski RJ, Atassi B, et al. Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): safety, tumor response, and survival[J]. J Vasc Interv Radiol, 2005, 16(12): 1627-1639. DOI: 10.1097/01.RVI.0000184594.01661.81.
[24]	Carr BI. Hepatic arterial 90Yttrium glass microspheres (Therasphere) for unresectable hepatocellular carcinoma: Interim safety and survival data on 65 patients[J]. Liver Transplant, 2004, 10(Supplement 2): S107-S110. DOI: 10.1002/lt.20036.
[25]	Walker LA. Radioactive yttrium 90: a review of its properties, biological behavior, and clinical uses[J]. Acta Radiol Ther Phys Biol, 1964, 2: 302-314. DOI: 10.1080/02841866409134063.
[26]	Salem R, Lewandowski RJ, Mulcahy MF, et al. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes[J]. Gastroenterology, 2010, 138(1): 52-64. DOI: 10.1053/j.gastro.2009.09.006.
[27]	Kim E, Sher A, Abboud G, et al. Radiation segmentectomy for curative intent of unresectable very early to early stage hepatocellular carcinoma (RASER): a single-centre, single-arm study[J]. Lancet Gastroenterol Hepatol, 2022, 7(9): 843-850. DOI: 10.1016/S2468-1253(22)00091-7.
[28]	Bekki Y, Marti J, Toshima T, et al. A comparative study of portal vein embolization versus radiation lobectomy with Yttrium-90 micropheres in preparation for liver resection for initially unresectable hepatocellular carcinoma[J]. Surgery, 2021, 169(5): 1044-1051. DOI: 10.1016/j.surg.2020.12.012.
[29]	Gabr A, Kulik L, Mouli S, et al. Liver transplantation following yttrium-90 radioembolization: 15-year experience in 207-patient cohort[J]. Hepatology, 2021, 73(3): 998-1010. DOI: 10.1002/hep.31318.
[30]	van Hazel GA, Heinemann V, Sharma NK, et al. Sirflox: randomized phase iii trial comparing first-line mFOLFOX6 (plus or minus bevacizumab) versus mFOLFOX6 (plus or minus bevacizumab) plus selective internal radiation therapy in patients with metastatic colorectal cancer[J]. J Clin Oncol, 2016, 34(15): 1723-1731. DOI: 10.1200/JCO.2015.66.1181.
[31]	Cwikla JB, Sankowski A, Seklecka N, et al. Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase Ⅱ study[J]. Ann Oncol, 2010, 21(4): 787-794. DOI: 10.1093/annonc/mdp372.
[32]	Edeline J, Bridgewater J, Campillo-Gimenez B, et al. Chemotherapy with or without selective internal radiation therapy for intrahepatic cholangiocarcinoma: data from clinical trials[J]. Hepatology, 2024, 79(1): 96-106. DOI: 10.1097/HEP.0000000000000544.
[33]	Stokes SM, Massarweh NN, Stringham JR, et al. Clinical-pathologic correlation and guideline concordance in resectable non-small cell lung cancer[J]. Ann Thorac Surg, 2019, 108(3): 837-844. DOI: 10.1016/j.athoracsur.2019.03.062.

Please choose a citation manager

Content to export